Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 12, Pages 4427
Publisher
MDPI AG
Online
2020-06-23
DOI
10.3390/ijms21124427
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
- (2020) Yi Yang et al. Frontiers in Pharmacology
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- Spatial Dose Patterns Associated with Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Radiation Therapy with Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer
- (2019) Giuseppe Palma et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
- (2019) Sara I. Pai et al. Journal for ImmunoTherapy of Cancer
- The Clinical Trial Landscape for Melanoma Therapies
- (2019) Sonia Wróbel et al. Journal of Clinical Medicine
- Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
- (2019) Rama Soundararajan et al. Cancers
- Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses
- (2019) Chikara Ohyama et al. International Journal of Clinical Oncology
- Clinical update on head and neck cancer: molecular biology and ongoing challenges
- (2019) Elham Alsahafi et al. Cell Death & Disease
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
- (2019) Hannah L. Buckley et al. BMC CANCER
- Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS
- (2019) Digdem Yoyen-Ermis et al. Scientific Reports
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials
- (2018) Vivek Verma et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity
- (2018) Kevin Diao et al. JOURNAL OF NEURO-ONCOLOGY
- Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
- (2018) Yuka Asano et al. Journal of Translational Medicine
- Nivolumab plus ipilimumab in metastatic colorectal cancer
- (2018) Elizabeth Gourd LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers
- (2018) Akshay Sood et al. Current Urology Reports
- Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?
- (2018) Kulmira Nurgali et al. Frontiers in Pharmacology
- Immune checkpoint inhibitors in small cell lung cancer
- (2018) Suchita Pakkala et al. Journal of Thoracic Disease
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
- (2018) Luana Calabrò et al. Lancet Respiratory Medicine
- Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
- (2018) Richard P. Tobin et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in Antibody Therapeutics Targeting Small-Cell Lung Cancer
- (2018) HONGYANG LU et al. Advances in Clinical and Experimental Medicine
- Management of immune-related adverse events resulting from immune checkpoint blockade
- (2018) Barouyr Baroudjian et al. Expert Review of Anticancer Therapy
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma
- (2018) Su Yeon Yeon et al. PATHOLOGY RESEARCH AND PRACTICE
- Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis
- (2018) Zhe Geng et al. Oncotarget
- B2M, JAK2 and MET in the genetic landscape of immunotolerance in lung cancer
- (2018) Montse Sanchez-Cespedes Oncotarget
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions
- (2017) Stephen Marabondo et al. Expert Opinion On Drug Safety
- Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Epidemiology of urothelial carcinoma
- (2017) Jun Miyazaki et al. INTERNATIONAL JOURNAL OF UROLOGY
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer
- (2017) Robert T. Dess et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
- (2017) Naziheh Assarzadegan et al. VIRCHOWS ARCHIV
- Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
- (2017) Liting Guo et al. Journal of Cancer
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Head and neck cancer: improving outcomes with a multidisciplinary approach
- (2017) Cristiana Lo Nigro et al. Cancer Management and Research
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies
- (2016) Noura Choudhury et al. CANCER SCIENCE
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
- (2016) B. Ingold Heppner et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
- (2016) Eri Matsuki et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitors: a patent review (2010-2015)
- (2016) Matthieu Collin EXPERT OPINION ON THERAPEUTIC PATENTS
- Gel of chamomile vs. urea cream to prevent acute radiation dermatitis in patients with head and neck cancer: a randomized controlled trial
- (2016) Elaine Barros Ferreira et al. JOURNAL OF ADVANCED NURSING
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
- (2016) Omar Hasan Ali et al. OncoImmunology
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
- (2015) Shohei Eto et al. Gastric Cancer
- Hodgkin Lymphoma: Diagnosis and Treatment
- (2015) Stephen M. Ansell MAYO CLINIC PROCEEDINGS
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- (2015) Evan J. Lipson et al. SEMINARS IN ONCOLOGY
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers
- (2013) Ronald Scheff et al. SEMINARS IN INTERVENTIONAL RADIOLOGY
- Hodgkin's lymphoma in adults
- (2012) William Townsend et al. LANCET
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
- (2012) James W. Hodge et al. SEMINARS IN ONCOLOGY
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
- (2011) Ahmad Tarhini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Assessment of the Evolution of Cancer Treatment Therapies
- (2011) Manuel Arruebo et al. Cancers
- Head and neck cancer
- (2010) David M. Cognetti et al. CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
- (2009) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now